JAB-BX400 / Jacobio Pharma - LARVOL DELTA

(1) INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024; (2) RESIGNATION OF NON-EXECUTIVE DIRECTOR; AND 3) CHANGE IN THE COMPOSITION OF THE REMUNERATION COMMITTEE AND THE NOMINATION COMMITTEE (HKEXnews) - "JAB-BX102 (anti-CD73 humanized monoclonal antibody)...Dose escalation for a Phase I/IIa trial has been finished in China and dose expansion trial is being planned in China....Clinical candidate for JAB-BX400 is expected to be nominated in the second half of 2024."

Pipeline update • Trial status • Oncology • Solid Tumor

Jacobio Pharma Announces 2023 Annual Results (PRNewswire) - "KRASmulti inhibitor JAB-23E73: The IND application is expected to be submitted in Q2 2024; Clinical candidate for HER2-STING iADC JAB-BX400 is expected to be nominated in the second half of 2024."

Clinical • IND • Oncology • Solid Tumor

Jacobio Pharma Announces 2023 Interim Results (PRNewswire) - "Development of pre-clinical stage products:...iADC projects:...Preclinical studies have shown that JAB-BX400 is effective against DS8201 resistant tumor models, and the IND application will be submitted in 2024-2025."

IND • Oncology • Solid Tumor

Jacobio Pharma Announces 2022 Interim Results (PRNewswire) - "Jacobio is currently developing HER2 STING iADC JAB-BX400 and CD73-STING iADC JAB-X1800. IND applications for these two programs are expected to be submitted in 2024."

IND • Oncology